ACS infectious diseases · 2018
Drug Discovery for Kinetoplastid Diseases: Future Directions.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rao Srinivasa P S, Barrett Michael P, Dranoff Glenn, Faraday Christopher J, Gimpelewicz Claudio R, Hailu Asrat, Jones Catherine L, Kelly John M, Lazdins-Helds Janis K, Mäser Pascal, Mengel Jose, Mottram Jeremy C, Mowbray Charles E, Sacks David L, Scott Phillip, Späth Gerald F, Tarleton Rick L, Spector Jonathan M, Diagana Thierry T
Аннотация
Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host-parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.